# Oncimmune Holdings plc Demonstrate the potential of its technology

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-demonstrate-potential-technology/412734226
- Published: 2017-08-29T07:17:54+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT® platform technology, and Scancell 
Holdings plc, (‘Scancell’) the developer of novel immunotherapies for the treatment
of cancer, announced today the presentation of data on the use of Oncimmune’s autoantibody
technology to successfully predict disease recurrence in subjects undergoing SCIB1
immunotherapy for malignant melanoma. The data will be presented at the Cambridge
Healthtech Institute (CHI) Immuno-Oncology Summit 2017 on August 29th 2017.

The collaborative study, which also included a team at the University of Nottingham,
developed a method using a panel of seven tumour associated autoantibodies to predict
disease recurrence in patients with resected Stage III/IV melanoma treated with 
Scancell’s SCIB1 immunotherapy. Whilst Phase I/II trials with SCIB1 have been highly
encouraging, this additional information potentially enables the identification 
of patients prior to commencement of therapy who are most likely to respond to treatment
in future clinical trials with SCIB1.

> **Geoffrey Hamilton-Fairley, Oncimmune Holdings plc Chief Executive Officer, commented:**“
> This is the first of a number of companion diagnostics programmes we are undertaking,
> having shown with internal data that by using Oncimmune’s autoantibody platform
> it is possible to differentiate patient responses to a range of cancer treatments.
> While validation on a larger data set is necessary, these results indicate that
> in this case it was possible to identify patients who are most likely to respond
> to Scancell’s SC1B1 and thus further demonstrate the potential of our technology
> in this application.”
> **Dr Richard Goodfellow, CEO of Scancell added:** “If this preliminary data is
> confirmed in a larger clinical study, it has the potential to improve the design
> of future clinical trials using SCIB1 by selecting patients most likely to positively
> respond to our novel treatment and thereby increase the chances of a successful
> outcome.”

Share on: